Interpace Biosciences, Inc. Announces Management Changes
November 25, 2020 at 08:28 am
Share
On November 23, 2020, in connection with his retirement, Jack E. Stover announced his decision to resign as President and member of the Board of Directors of Interpace Biosciences, Inc. and its subsidiaries, effective December 1, 2020. On that same date, the Board appointed Mr. Thomas W. Burnell as the company’s successor President and nominated and elected him as a member of the Board, in each case effective December 1, 2020. Mr. Burnell, age 58, has extensive leadership experience in the healthcare, biotechnology, laboratory sciences and manufacturing sectors. From October 15, 2019 until November 30, 2020, he served and will serve as President and Chief Executive Officer of Cardiovascular Clinic of Nebraska LLC, a medical treatment facility focused on diagnosis and treatment of cardiac and vascular disorders, and from October 2, 2017 until November 29, 2017 he served as Chief Executive Officer and a director of True Nature Holding, Inc., a public company now known as Mitesco, Inc. that focuses on development and acquisition of innovative technologies. From July 16, 2016 until March 31, 2017, Mr. Burnell was the President of Boston Heart Diagnostics, a diagnostics subsidiary of Eurofins Scientific, Inc. In connection with Mr. Stover’s resignation as a Class III director effective December 1, 2020, Mr. Burnell was nominated and elected as a Class III director by the Board on November 23, 2020, effective on December 1, 2020, for a term to continue until the next election of the Class III directors at the 2023 annual meeting of the Company’s stockholders, subject to the election and qualification of his successor and to his earlier death, resignation or removal.
Interpace Biosciences, Inc. provides personalized medicine and offers specialized services along the therapeutic value chain from early diagnosis and prognostic planning to targeted therapeutic applications. Its clinical services, through Interpace Diagnostics, provide clinically useful molecular diagnostic tests, bioinformatics and pathology services for evaluating the risk of cancer by leveraging the technology in personalized medicine for improved patient diagnosis and management. It has five commercialized molecular tests and one test in a clinical evaluation program: PancraGEN, PanDNA, ThyGeNEXT, ThyraMIR v2, RespriDX, and BarreGEN. PancraGEN is for the diagnosis and prognosis of pancreatic cancer from pancreatic cysts. PanDNA is a molecular only version of PancraGEN that provides physicians a snapshot of a limited number of factors. ThyGeNEXT is for the diagnosis of thyroid cancer from thyroid nodules. RespriDX differentiates lung cancer of primary versus metastatic origin.